Patients with immune-mediated inflammatory diseases receiving cytokine inhibitors have low prevalence of SARS-CoV-2 seroconversion
Patients with immune-mediated inflammatory diseases receiving cytokine inhibitors have low prevalence of SARS-CoV-2 seroconversion
复制标题
DOI：
10.1038/s41467-020-17703-6
复制
发表时间：
2020-07-24
影响因子：
16.6
通讯作者：
Schett, Georg
中科院分区：
文献类型：
--
作者：
Simon, David;Tascilar, Koray;Schett, Georg
关节、肠道和皮肤的免疫介导的炎性疾病（IMID）用炎性细胞因子的抑制剂治疗。这些细胞因子参与了2019冠状病毒病（COVID-19）的发病机制。研究IMID中的抗SARS-CoV-2抗体应答，我们观察到与未接受此类抑制剂的患者和两个健康对照人群相比，接受细胞因子抑制剂治疗的IMID患者中SARS-CoV-2血清转化的发生率降低，尽管社会暴露相似。因此，细胞因子抑制剂似乎至少部分地保护免受SARS-CoV-2感染。细胞因子风暴似乎是严重COVID-19病理的共同特征。在这里，作者显示，如果已经接受细胞因子或JAK抑制剂治疗，则大量免疫介导的炎症性疾病患者的SARS-CoV 2阳性率降低，这表明这些治疗可以安全地继续进行，并且可能对COVID 19具有保护作用。
Immune-mediated inflammatory diseases (IMIDs) of the joints, gut and skin are treated with inhibitors of inflammatory cytokines. These cytokines are involved in the pathogenesis of coronavirus disease 2019 (COVID-19). Investigating anti-SARS-CoV-2 antibody responses in IMIDs we observe a reduced incidence of SARS-CoV-2 seroconversion in IMID patients treated with cytokine inhibitors compared to patients receiving no such inhibitors and two healthy control populations, despite similar social exposure. Hence, cytokine inhibitors seem to at least partially protect from SARS-CoV-2 infection. Cytokine storm seems to be a common feature of severe COVID-19 pathology. Here, the authors show a reduced rate of SARS-CoV2 positivity in a large population of patients with immune-mediated inflammatory diseases if they are already being treated with cytokine or JAK inhibitors, indicating these treatments are safe to continue and are possibly protective against COVID19.